Metabolic Syndrome Arrays from Randox Biosciences
Metabolic syndrome is described as a combination of diabetes, high blood pressure and obesity. As result of three health conditions going on, it puts the individual at greater risk of developing coronary heart disease, stroke and many other risks. 1 As well as developing additional health conditions it can cause damage to the blood vessels, the blood pressure damages the blood vessels, the obesity causes a lot of strain on the blood vessels and the heart.2 Therefore, can result in serious long-term risks.
This serious health condition is very common, and studies state that it affects about 23% of adults. 3One in four adults in the UK are currently living with metabolic syndrome and often becomes more common with age2.
Usually it affects those who are overweight or considered obese, have an unbalanced diet containing high levels of sugar and fat and have high cholesterol and extremely high blood pressure2 therefore, the condition can be prevented by reducing the risks.
1 According to the NHS, metabolic syndrome occurs when a person has three or more of the following measurements:
-Abdominal obesity (Waist circumference of greater than 40 inches in men, and greater than 35 inches in women)
-Triglyceride level of 150 milligrams per deciliter of blood (mg/dL) or greater
– HDL cholesterol of less than 40 mg/dL in men or less than 50 mg/dL in women
– Systolic blood pressure (top number) of 130 millimeters of mercury (mm Hg) or greater, or diastolic blood pressure (bottom number) of 85 mm Hg or greater
There are many ways to prevent metabolic syndrome from developing, making lifestyle changes for example, ensuring their weight is healthy by increasing physical exercise, eating a well-balanced healthy diet containing whole grains, fruit, vegetables and fish and finally, visiting the GP to monitor and manage blood glucose, blood cholesterol and blood pressure, quit smoking and managing your stress.
Randox offers the Evidence Evolution including two Metabolic Syndrome Arrays which allows multiplex testing from a single sample allowing rapid turnaround time and are suitable for both serum and plasma samples.
Metabolic Syndrome Array I
- Interleukin-6 (IL-6)
- Plasminogen Activator Inhibitor-1 (PAI-1)
Metabolic Syndrome Array II
- C-reactive Protein (CRP)
- Cystatin C
For more information on our Evidence Series or Metabolic Syndrome Range of Assays, contact us at EvidenceSeries@randox.com
Randox Biosciences Products and Services
Want to know more about Randox?
Contact us or visit our homepage to view more.
Drug Induced Kidney Injury (DIKI) panel is the latest innovative panel created by Randox Laboratories. It has been developed to identify four early stage markers of DIKI by screening for the biomarkers KIM-I, NGAL, Cystatin C, and Clusterin.
Drug induced nephrotoxicity is a common problem in clinical trials and clinical medicine and the incidence of drug-related acute kidney injury may be as high as 60%.1 With the success rates of phase I clinical trials sitting at just under 10% and 75 – 80 % of failures, from phase I – III, resulting from problems with efficacy and/or safety the need to improve patient safety and detect kidney injury as early as possible is vital.2
The novel Randox Drug Induced Kidney Injury Array (DIKI) test allows superior monitoring of nephrotoxicity for enhanced safety in drug development. The biomarkers have been identified as more sensitive than transitional testing methods to enhance accurate diagnosis of DIKI. The DIKI test will be able to identify the levels of toxicity present in the kidneys which is classified as one of the most common side effects of drug development trials.
In 2017, 75% to 80% of clinical trials failed due to unacceptable safety.2 The four biomarkers on the DIKI panel are recommended by the U.S. Food and Drug Administration and the European Medicines Agency. The biomarkers have been acknowledged as more sensitive than traditional creatinine and more specific for diagnosis and prediction monitoring. DIKI has a faster turn-around time than creatinine. The levels of serum creatinine take a lengthy 48 hours to rise in the urine of someone with Drug Induced Kidney Injury. Whereas the biomarkers, such as NGAL, on the new DIKI biochip from Randox, can be present in urine within hours following initial kidney insult. The Randox Biochip test is performed in under 3 hours. Randox Clinical Laboratory Services (RCLS) is a state of the art ISO 17025 accredited central laboratory with unrivalled facilities built upon Randox Laboratories experience and is Randox’s latest offering, dedicated to providing a clinical laboratory service designed to meet the time sensitive, bespoke requirements of clinical and research projects globally.
If you are facilitating a clinical trial and want to test for drug induced kidney injury RCLS is your out-sourcing testing solution. RCLS can assist you to ensure the toxicity and efficacy of your drug helping you to save money and time. With a greater understanding of human complexity, pharmaceutical companies are now focusing on developing safer drugs. The early detection of DIKI can reduce cost and time and will allow a safe drug in the market
If you are conducting a clinical trial or would like more information on RCLS contact firstname.lastname@example.org.
Randox Biosciences introduces the innovative Randox Drug Induced Kidney Injury Array (DIKI). The new panels allow superior monitoring of nephrotoxicity for enhanced safety in drug development. It has been developed to identify four early stage markers of DIKI by screening for the biomarkers KIM-I, NGAL, Cystatin C, and Clusterin which have been identified as more sensitive than transitional testing methods to enhance accurate diagnosis of DIKI.
Our Biochip Array Technology enables multiplex immunoassay testing. The DIKI panel of 4 markers is combined on a single biochip, enabling simultaneous results from each patient sample, delivering:
- Excellent inter-assay precision and required sensitivity
- Superior specificity
- Lower sample volume
- Fast turnaround time
- Safer drug development
With the number of hospitalised patients who develop a drug-induced renal problem due to the numbers of potent drugs have been added to the therapeutic arsenal in recent year1 – the DIKI can have a detrimental effect on a person’s health and wellbeing. Blakely stated that “drug-induced nephrotoxic contributes to 8 to 60% of all cases of AKI seen on the intensive care unit (ICU)”.2 Randox offers a 4-plex Drug Induced Kidney Injury test which detects early stage toxicity across the nephron, assisted through composite measurement. Earlier and more reliable detection of drug-induced kidney injury would improve clinical care and help to streamline drug-development. (Dieterle et al., 2010)3.
The poor sensitivity of serum creatinine for detecting and monitoring DIKI is well documented in academic journals. As a result, for early phase trials European Medicines Agency (EMA) and Food and Drug Administration (FDA) are encouraging the use of more novel urinary biomarkers alongside conventional safety monitoring. The new panel will be able to identify the levels of toxicity present in the kidneys which is classified as one of the most common side effects of drug development trials.
The new Randox Drug Induced Kidney Injury (DIKI) panel can help you conduct clinical trials safer and faster. For more information contact email@example.com.
For our 2018/19 placement students, their year with Randox is almost at an end.
To mark their time with us and wish them the best of luck with their future studies, we took the opportunity to speak with one of our placement students in the sales team, to give us an insight of her experience during a Randox placement year.
Meet Kathryn Wilson, Business Placement Sales Executive for Randox Biosciences.
Hi Kathryn, can you tell us a little bit about yourself?
I am a 21-year-old student studying Bsc Equine and Veterinary Bioscience at Aberystwyth University in Wales. In September 2018 I began working in the Biosciences division of Randox Laboratories, specifically working on the release of new molecular technologies for clinical diagnostics. As part of a newly formed sales team, my focus is on the diagnostics market in Ireland.
Why did you want to forge a career in sales?
Whilst studying my bio-veterinary degree my only focus had been on science, so I was keen to broaden my horizons and explore opportunities in a business role for a company involved in the life-sciences industry. Initially, I was tentative of a role in sales, but I knew it would be a good way to develop a broad knowledge of business and the industry, and develop new skills.
Why did you decide to take your placement year with Randox?
Randox was a perfect fit for me, as a global scientific company based in Northern Ireland. I was looking for a placement that would allow me to spend time at home before returning to Wales for university.
I was intrigued by their range of products and diverse market presence in industries such as pharmaceuticals, biotech, research and healthcare. It seemed like a good company to gain an insight into new research in a variety of career sectors.
Describe a typical day as a Business Placement Sales Executive.
My role has evolved as we have moved through the different stages of product development throughout the year. Initially, when I first joined the team, we were in the planning stage. This involved mapping potential contacts and key sites in Ireland, and developing a sales strategy.
As this is a new venture for Randox the role also involved educating the market on our technology and creating awareness in all potential points of sale. This educational aspect of my job involved regular trips and meetings across Ireland, and frequent UK team meetings to discuss market feedback and problem solve. It’s important that we have been able to adapt our sales strategy for the specific healthcare areas -from public to private and point-of-care to large laboratories. Coming into the final month of my placement we are now prepared for product release with confirmed validation studies and initial placements, and significant interest across Ireland.
What are some examples of the tasks and responsibilities of your role?
There has been a range of ongoing tasks throughout the year to facilitate a busy and growing division. I was given the responsibility of forecasting, logging orders and organising meetings, and have been involved in internal decision-making processes alongside management. I have also helped to manage the university contracts in Ireland for our lab equipment, reagents and outsourcing some testing for specific studies.
Before I finish my placement I’m researching the market for upcoming arrays for launch next year, and planning a final trip in Ireland.
What was the most exciting part of your placement with Randox Biosciences?
The opportunity to travel around Ireland and London has been excellent. To date I have participated in over 10 conferences on behalf of Randox. Highlights for me have been corporate hospitality with potential customers at the Randox Health Grand National, and presenting at the first Infectious Disease Forum for Randox, in front of representatives from microbiology sites across Ireland.
I was also trusted to conduct a trip on my own around Donegal and Sligo, coupled with a visit to our Donegal R&D site, Randox Teoranta in Dungloe, to learn about future veterinary arrays in development.
It has been a privilege to be able to work with such a diverse range of people – from the scientists developing the products, to the sales team specialising in markets across the globe. There are so many different career paths here at Randox.
What has been the most challenging aspect of your time at Randox Biosciences?
I have been challenged to quickly adapt to the business environment and gain an in-depth understanding of the wide range of products. I have been pushed outside my comfort zone to discuss with customers, present to the team and take responsibility of the day-to-day tasks.
Knowing the new molecular diagnostics range, infectious disease panels, and competitors in the market well enough to be confident in front of potential customers on my own, has also been a challenge. Hard work at Randox is acknowledged however, and I was awarded runner-up Business Student of the Year.
What is the best thing about Randox and would you recommend this placement to other students?
The best thing about a placement with Randox is that you will be given as many opportunities as you are willing to take. They are very supportive and will push you as much as any other member of the team.
As a non-business student this year has given me a wealth of insight into the workings of a global company, as well as furthering my scientific knowledge and interests in many aspects of the industry.
I would recommend a Randox placement for students who are keen to gain as much experience as possible in a global company focused on new and exciting health research.
What are your goals for the future?
My experience at Randox has given me an excellent insight into the world of business in the biosciences industry, and has prepared me well to build a career in this exciting industry. I think that the experience gained through Randox will be applicable to many life sciences sectors which I would like to explore further.
Although I am not sure what the future may hold, in the shorter term I am looking forward to returning to finish my final year at Aberystwyth.
For more information about Randox Biosciences and what career opportunities we offer please contact firstname.lastname@example.org
What is Familial Hypercholesterolemia?
Familial Hypercholesterolemia (FH) is a genetic condition which is passed down from the parents’ genes. The British Heart Foundation has highlighted that FH is caused by a genetic mutation which means the liver is unable to remove excess ‘bad’ cholesterol (LDL), therefore, the LDL level in the blood remains high.2 Someone who suffers with FH would have high cholesterol from birth which can cause other health issues including heart and circulatory disease.
Heart UK states that more than 260,000 people in the UK may have FH. However, less than 10% of this number have been diagnosed and therefore, may not be aware of their condition.3 However, to date there are no clear symptoms if someone has FH until it is considered too late.
Familial Hypercholesterolemia (FH) symptoms
- Swollen tendons/fatty lumps on the knuckles of your hands, at the back of your ankles and knees
- Cholesterol deposits around the eye-lids (looks like pale and yellowish patches)
- Grey-white cholesterol deposits around the corneas
If untreated, about 50% of men and 30% of women with FH will develop coronary heart disease by the time they are 55. More worryingly, on average in the UK, one person a day with FH has a heart attack. About a third of people don’t survive their first heart attack, and many who do survive will have damaged hearts.
The good news is that a 2008 study part-funded by the BHF found that people with FH who are diagnosed and treated before they develop heart disease generally live as long as people who don’t have FH. That’s why it is vitally important to get diagnosed as early as possible.
How Randox Biosciences can help
Randox Biosciences offers the Familial Hypercholesterolemia (FH) Arrays I & II to help encourage early diagnosis with rapid turnaround time. This allows results to be reported within days compared with NHS waiting lists which can be substantially longer.
Our two arrays are rapid, simple and accurate which enables the simultaneous detection of 40 FH-causing mutations (20 mutations per array) within the LDLR, ApoB and PCSK9 genes.
The mutational status can be determined rapidly from a single test, with a reduced need for confirmatory testing. Genetic analysis for FH mutations also allows for more accurate diagnosis compared to lipid profiling.
Familial Hypercholesterolemia (FH) Arrays I & II:
LDLR – 38 mutations
APOB – 1 mutation
PCSK9 – 1 mutation
To find out more about the products that we offer, email us email@example.com
What is Alzheimer’s Disease?
Alzheimer’s Disease is a progressive disease and is one of the most common kinds of dementia.
Our brains are made up of billions of tiny nerve cells which connect to each other. However, if you have Alzheimer’s Disease the connections between the cells are lost, which results in the loss of brain tissue and causes nerve cells to die1.
The brain is responsible for sending signals between cells. Those who suffer with Alzheimer’s have less ‘chemical messengers’ in their brain, so the signals are not passed on as well1.
The statistics of those who suffer with dementia is increasingly high and the figure is set to rise in the foreseeable future. Over 850,000 people are living with dementia in the UK. Studies states that one million people in the UK will have dementia in 2025 and this will increase to two million by 2050.2
Symptoms of Alzheimer’s Disease
The symptoms of Alzheimer’s disease are divided into 3 main stages; early symptoms, middle-stage symptoms and later symptoms.
In the early stages, the main symptom of Alzheimer’s disease is memory lapses which can increase anxiety or agitation. In the early stages, it is often mistaken that the person is forgetful and aren’t aware they are suffering with Alzheimer’s. The typical signs are listed below:3
- forget about recent conversations or events
- misplace items
- forget the names of places and objects
- have trouble thinking of the right word
- ask questions repetitively
- show poor judgement
- become less flexible and more hesitant to try new things
As the disease progresses, the symptoms will gradually get worse. Memory problems will get worse which can make it difficult for the person who suffers with the disease to remember names of their loved ones, recent events and even remember birthdays and anniversaries. More symptoms such as the following will develop;3
- increasing confusion and disorientation – for example, getting lost, or wandering and not knowing what time of day it is
- obsessive, repetitive or impulsive behaviour
- delusions or feeling paranoid and suspicious about carers or family members
- problems with speech or language
- disturbed sleep
- changes in mood
- difficulty performing simple tasks and may need additional support e.g. help with eating, getting dressed etc.
In the later stages of Alzheimer’s disease, the symptoms become increasingly severe and patients will need full-time care and assistance. It will be problematic for the individual to do basic everyday tasks such as getting changed, going to the toilet, getting washed and feeding themselves. They could lose their speech, and have difficulty eating and swallowing which can result in severe weight loss.
How Randox can help
Randox want to help. Our Evidence immunoanalyser has revolutionised laboratory screening worldwide with the capability to process 3,960 tests per hour and a sample capacity of 360. We offer the Apolipoprotein E4 (ApoE4) Array for Alzheimer’s genetic risk assessment, which is a research use-only product developed for the Evidence Investigator. The ApoE4 Array measures both total ApoE protein levels and ApoE4 protein levels directly from plasma samples and using a ratio can classify patients as negative or positive for ApoE4. In turn we can then assess their risk for the development of Alzheimer’s disease.
For further information about the Randox Alzheimer’s Array or our Evidence Investigator, please email firstname.lastname@example.org
May is National Cystic Fibrosis (CF) Awareness Month. The purpose of having the awareness month is to educate and raise additional awareness to the public about the horrible disease and how it affects those who suffer. According to the Cystic Fibrosis Foundation, more than 30,000 people are living with cystic fibrosis. More than 75% of these people are diagnosed in their early childhood 1.
What is CF?
Cystic Fibrosis is a genetic, life-threatening disease which affects the respiratory and digestive system. A person with CF is born with the condition and therefore it is not possible to catch it from someone else. The gene affected by CF controls the movement of salt and water in and out of cells, which results in a build-up of thick sticky mucus in the lungs, digestive system and other organs. This causes a wide range of challenging symptoms affecting the entire body.2
Symptoms of CF:
There are many symptoms to Cystic Fibrosis which can make life for someone who suffers with CF challenging. The build-up of sticky mucus in the lungs can make breathing difficult and clog up the pancreas which as a result can increase the risk of developing a lung infection or worse, death. This can make it difficult for those who have CF to absorb nutrients from food properly and therefore they must eat more calories to avoid malnutrition. Other symptoms include the following:3
- recurring chest infections
- wheezing, coughing, shortness of breath and damage to the airways (bronchiectasis)
- difficulty putting on weight and growing
- diarrhoea, constipation, or large, smelly poo
- a bowel obstruction in new-born babies (meconium ileus) – surgery may be needed
Complications of CF:
3People with CF also have a higher risk of developing other conditions. These include:
- weak and brittle bones (osteoporosis)– medicines called bisphosphonates can sometimes help
- diabetes– insulin and a special diet may be needed to control blood sugar levels
- nasal polyps and sinus infections – steroids, antihistamines, antibiotics or sinus flushes can help
- liver problems
- fertility problems – it’s possible for women with CF to have children, but men won’t be able to father a child without help from fertility specialists (see a doctor or fertility specialist for more advice)
4There is no cure for CF, but with improved treatment and management people with Cystic Fibrosis are living longer. It’s thought that children born with CF nowadays are likely to live to an average age of over 50 years old.
How we can help:
Randox Biosciences offer the Vivalytic with the Chronic Lung Disease cartridge, in combination with our intelligent Biochip Array Technology which detects 132 pathogens. The 132 species are simultaneously detected across this 320 Array including bacterial, viral, fungal targets and an antibiotic resistance marker from a single sputum sample!
A stroke can happen to anyone at any time. It is a serious life-threatening medical condition which occurs when the blood supply to part of the brain is cut off. It causes the brain cells to die resulting the abilities controlled by the brain such as memory and muscle control to become damaged. 1
According to the Stroke Association, strokes are considered the fourth biggest killer in the UK. There are more than 100,000 strokes each year which equals around one stroke every five minutes.2 Some people recover from the condition; however, two thirds of the survivors will have some sort of disability. 3
There are two mains types of strokes which are defined as “Ischemic strokes” and “Hemorrhagic stroke”.
Ischemic stroke is by far the most common kind of stroke, accounting for about 88% of all cases4. Ischemic strokes occur when there is an artery blockage which cuts off the blood supply to certain areas of the brain, which then results in brain cells being unable to make energy and dying. The arteries are vital for the brain as they bring fresh blood from the heart and lungs carrying oxygen and nutrients and taking away carbon dioxide and cellular waste. 4
The hemorrhagic stroke is less common but is more severe as there is a higher risk of dying within the first three months. It is when a blood vessel ruptures causing a bleed inside the brain, resulting in the death of brain cells. They are responsible for 40% of all stroke deaths.5
Symptoms of Stroke
The most commons symptoms of a stroke are:
- Weakness or numbness of the face, arm, or leg on one side of the body
- Loss of vision or dimming in one or both eyes
- Loss of speech, difficulty talking, or understanding what others are saying
- Sudden, severe headache with no known cause
- Loss of balance or unstable walking, usually combined with another symptom
Many risk factors can increase your chance of having a stroke. Some life style factors include being obese/overweight, not exercising enough, heavy drinking, use of illegal drug such as cocaine, cigarette smoking, high cholesterol, diabetes, disruptive sleeping pattern and family history of having stroke or heart attack.
Up to 80% of strokes are preventable. 3 There are simple healthy lifestyle recommendations that could decrease your chances of developing a stroke in the future which include:
- Controlling your blood pressures as it is one of the biggest preventions of developing a stroke.
- Maintaining a healthy weight through a well-balanced diet involving rich fruit and vegetables as well as decreasing the amount of cholesterol, saturated fat and sodium intake.
- Exercising regularly and staying within a good routine will also reduce your risk of having a stroke.
- Quitting tobacco usage and decreasing alohcal intake will help as well as regular usage increases the risk of having high blood pressure.
- Avoid taking illegal drugs such as cocaine as it reduces your blood flow which narrows the arteries.
Randox Biosciences offers a stroke array which works quickly to determine which type of stroke a person has experienced. Ischaemic stroke can be treated by thrombolysis and, with early usage, it can help limit stroke damage and disability.
However, inappropriate administration of thrombolytic therapy can cause serious adverse effects, including intracranial haemorrhage. Hence, there is an unmet clinical need for a rapid and highly sensitive testing that complements existing CT scanning approaches and facilitate the definitive identification of ischaemic stroke patients.
Randox’s innovative Biochip Array Technology enables simultaneous detection of eight stroke biomarkers from a single blood sample.
The eight biomarkers that can be detected in a single blood sample are:
- Glutathione S-Transferase-Pi (GSTP-Pi)
- Nucleoside Diphosphate Kinase A (NDKA)
- Parkinson Protein 7 (PARK7)
- Glial Fibrillary Acidic Protein (GFAP)
- Interleukin 6 (IL-6)
- Heart Fatty Acid Binding Protein (H-FABP)
This year, National Brain Awareness Week runs from the 11th onto the 15th March 2019; a full week dedicated to brain health to increase public awareness of the progress and research of brain health.
Every single brain is unique and therefore, there are no two brains that are alike. The brain is an incredible and powerful organ which works throughout your life – starting from the womb to the end. It controls your body functioning in response to processing new information, developing new experiences and allowing you to understand and interact with the world. It contains one hundred billion nerve cells or neurons and each of the neurons can contact thousands of other cells via tiny structures called synapses. Our brains form a million new connections for every second of our lives.1
There are many conditions which can affect the brain including brain injuries, cerebrovascular injuries such as strokes or brain tumors, neurodegenerative disorders such as dementia or Parkinson’s disease, or even psychological conditions.
There is increasing evidence that the choices we make in life can have significant impacts on the health of our brain and bodies as we grow older. Doctors and scientific researchers have discovered that it’s possible to improve brain health and reduce the risk of dementia and age-related cognitive decline by making simple yet small lifestyle changes – for example, improving your physical exercise.
Physical experience is not only good for the heart but also has a positive impact on the brain as well. People who exercise regularly have a lower risk of developing Alzheimer’s disease as exercise improves blood flow and memory. Another way to improve your brain health is to get your eight hours of sleep. Poor sleeping patterns can increase your chances of developing the brain conditions highlighted above. Also, eating well and eating foods that improve brain function will go a long way – for example, berries, fish, turmeric, green tea, avocado, walnuts and even dark chocolate.
Caroline Abrahams, Director of Age UK said: ‘The changes that we need to make to keep our brains healthy are already proven to be good for the heart and overall health, so it’s common sense for us all to try to build them into our lives.’ 3
Randox Biosciences offers the Apolipoprotein E4 (ApoE4) Array. The Apolipoprotein E4 (ApoE4) Array is a research use-only product developed for the Evidence Investigator. The ApoE4 Array measures both total ApoE protein levels and ApoE4 protein levels directly from plasma samples and by using a ratio it can classify patients as negative or positive for ApoE4. In turn we can then assess their risk for the development of Alzheimer’s disease.
For further information about the Randox Alzheimer’s Array or our Evidence Investigator, please email email@example.com
Randox Biosciences is delighted to officially announce the launch of our new website which offers a sleek, simple yet informative platform to further your knowledge of our product range and how we can assist you.
After six months of hard work and dedication the website has a fresh look. The interactive aspect of the website provides an easy way for our visitors to learn about Randox Biosciences products and services.
The improved interactive navigation ensures the user enjoys a seamless transition through Randox Biosciences extensive range of products and services with a better experience for both mobile and desktop versions. Potential customers will be able to identify with ease which client segment they fit into – whether it be Academic Research, Biopharma or Clinical Laboratory, enjoying a fully responsive experience.
During the redesign of the Randox Biosciences website we ensured that the brand identity remained consistent throughout, incorporating the brand colours across the site. We in cooperated GIFS (Graphics Interchange Format or moving images) on the top of the homepage as the main header of the website to automatically attract visitors with a moving graphic.
The GIF represents the Biochip Array Technology and the two different diagnostics testing we offer at Randox Biosciences. The GIFs images were continued throughout the website to highlight the three industries we cater for. Brochure downloads are also available on the new website for customers to enhance their knowledge with more in-depth information of Randox’s products and services.
The incorporation of an overview video on the homepage enables website users to gain a snapshot view of Randox Biosciences products and services. The idea of presenting the video first is to allow the visitor to understand our company from a visual method rather than processing a lot of written information.
73% of consumers worldwide would prefer seeing a video than text because they are more “entertaining”.1 The video itself, captures exactly what Randox Biosciences is and what we do. A short yet effective video clearly illustrates the science behind of Randox Biosciences and how this reaches the patient through drug discovery and development.
Julie-Ann O’Hare, Director of Randox Biosciences, commented:
“I am thrilled with the final product of the website, which I hope our current and potential customers will utilise it with ease. The website is another aspect of aligning our marketing strategy and branding to ensure our messaging is clear, concise and consistent across the board. We look forward to the continuation of promoting Randox Biosciences in the digital landscape throughout 2019.”
An e-commerce section of the website is under construction for the sale of our BioReagent products, which they are very excited to launch upon completion in Q3.
Check out our new and improved website for yourself. It is available at: https://www.randoxbiosciences.com/. Also, to find out more email us at firstname.lastname@example.org